KWA
DFTX icon

Kingswood Wealth Advisors’s Definium Therapeutics DFTX Stock Holding History

Kingswood Wealth Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.48M Buy
31,444
+4,853
+18% +$120K 0.06% 316
2026
Q1 		$503K Buy
+26,591
New +$451K 0.02% 549

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Kingswood Wealth Advisors's DFTX Position: Q2 2026 in Review

Kingswood Wealth Advisors increased its Definium Therapeutics (DFTX) stake by 18% in Q2 2026, buying an estimated $120K and bringing the position to 31,444 shares worth $1.48M. The position accounts for 0.06% of the portfolio, ranked #316.

Kingswood Wealth Advisors first reported a position in DFTX in Q1 2026 and has held it in 2 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Kingswood Wealth Advisors held 31,444 shares of Definium Therapeutics worth $1.48M as of Q2 2026.
  • Kingswood Wealth Advisors bought 4,853 Definium Therapeutics shares in Q2 2026, an estimated $120K.
  • Definium Therapeutics made up 0.06% of Kingswood Wealth Advisors's portfolio in Q2 2026, its #316 holding.
  • Kingswood Wealth Advisors first reported a position in Definium Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Kingswood Wealth Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.